Catalyst Pharmaceuticals to Report Third Quarter 2022 Financial Results on November 9, 2022
Catalyst Pharmaceuticals (CPRX) will release its third quarter 2022 financial results on November 9, 2022, after market close. A subsequent conference call and webcast will occur on November 10, 2022, at 8:30 AM ET, where the management team will discuss the results and provide a corporate update. FIRDAPSE®, approved in 2018, is available for treating adults and children with Lambert-Eaton myasthenic syndrome in the U.S. and Canada. Forward-looking statements highlight potential risks that may affect results significantly.
- FIRDAPSE® is approved and commercially available in the U.S. and Canada.
- Catalyst is focused on developing a pipeline for rare diseases.
- Forward-looking statements indicate risks that could adversely affect future results.
Conference Call and Webcast to be held on November 10, 2022, at 8:30 AM ET
CORAL GABLES, Fla., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today announced that it will release its third quarter 2022 financial results after market close on Wednesday, November 9, 2022.
Catalyst's management team will host a conference call and webcast the following morning, Thursday, November 10, 2022, at 8:30 AM ET, to discuss the Company's financial results and provide a corporate update.
Conference Call & Webcast Details
| Date/Time: | November 10, 2022 at 8:30 AM ET |
| US/Canada Dial-in Number: | (866) 682-6100 |
| International Dial-in Number: | (862) 298-0702 |
A webcast and accompanying materials will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on the Catalyst website for 30 days following the date of the event.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, best-in-class medicines for rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA") and FIRDAPSE is commercially available in the United States as a treatment for adults and children ages six to seventeen with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.
For more information, visit the Company's website at www.catalystpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2021 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
Source: Catalyst Pharmaceuticals, Inc.
FAQ
When will Catalyst Pharmaceuticals release its Q3 2022 financial results?
What is the date of the Catalyst Pharmaceuticals conference call?
What is the stock symbol for Catalyst Pharmaceuticals?
What does Catalyst Pharmaceuticals focus on?
Is FIRDAPSE® available in Canada?
